1. Acura Pharmaceuticals Inc., 2011. Study AP-ADF-107, a phase II single-center, randomized, double-blind study in fasted and non-fasted healthy volunteers to evaluate the dose response for flushing and safety and tolerability of escalating doses of niacin. http://acurapharm.com/products/acurox-tablets/study-ap-adf-107/ (accessed 02.03.16.).
2. Altus Formulation Inc, 2016. Intellitab Abuse deterrent formulations. http://altusformulation.com/technologies/intellitab/ (accessed 23.03/16.).
3. Ion-exchange resins: carrying drug delivery forward;Anand;Drug Discov. Today,2001
4. Andersen, C., Lindhardt, K., Oevergaard, J.M., Lyhne-Iversen, L., Olsen, M.R., Haahr, A.M., Hemmingsen, P.K.H., 2009. Formulations and methods for the controlled release of active drug substances. Egalet Ltd, US8563038.
5. Crush Resistant Delayed-release Dosage Forms;Ashworth,2009